id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-5694-0009,FDA,FDA-2017-E-5694,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-09-17T04:00:00Z,2019,9,2019-09-17T04:00:00Z,,2019-09-17T14:07:48Z,,0,0,0900006483f873cb
FDA-2017-E-5694-0007,FDA,FDA-2017-E-5694,"Determination of Regulatory Review Period for Purposes of Patent
Extension; EUCRISA",Notice,Determinations,2019-02-12T05:00:00Z,2019,2,2019-02-12T05:00:00Z,2019-04-16T03:59:59Z,2019-04-10T01:03:15Z,2019-01956,0,0,0900006483a66139